2020
DOI: 10.1101/2020.09.22.307645
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin

Abstract: Ovarian cancer is the fifth most common cause of cancer deaths among American women. Platinum and taxane combination chemotherapy represents the first-line approach for ovarian cancer, but treatment success is often limited by chemoresistance. Therefore, it is necessary to find new drugs to sensitize ovarian cancer cells to chemotherapy. Persistent activation of Signal Transducer and Activator of Transcription 3 (STAT3) signaling plays an important role in oncogenesis. Using a novel approach called advanced mu… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 43 publications
0
2
0
Order By: Relevance
“…The HIPEC model that was adapted could forecast the bioactive utilisation of cisplatin by regression analysis [160]. Cisplatin combined with the taxanes is another chemotherapeutic regimen in attenuating OC, but its efficacy is reduced by chemoresistance of the OC cells [101]. LLL12B is a small molecule inhibitor of chemoresistance that showed improved sensitivity when administered in combination with both cisplatin and paclitaxel together compared to either cisplatin or paclitaxel alone [101].…”
Section: Chemoresistance To Cisplatin In Ovarian Cancermentioning
confidence: 99%
See 1 more Smart Citation
“…The HIPEC model that was adapted could forecast the bioactive utilisation of cisplatin by regression analysis [160]. Cisplatin combined with the taxanes is another chemotherapeutic regimen in attenuating OC, but its efficacy is reduced by chemoresistance of the OC cells [101]. LLL12B is a small molecule inhibitor of chemoresistance that showed improved sensitivity when administered in combination with both cisplatin and paclitaxel together compared to either cisplatin or paclitaxel alone [101].…”
Section: Chemoresistance To Cisplatin In Ovarian Cancermentioning
confidence: 99%
“…Cisplatin combined with the taxanes is another chemotherapeutic regimen in attenuating OC, but its efficacy is reduced by chemoresistance of the OC cells [101]. LLL12B is a small molecule inhibitor of chemoresistance that showed improved sensitivity when administered in combination with both cisplatin and paclitaxel together compared to either cisplatin or paclitaxel alone [101]. It suppressed cell viability and proliferation by downregulating the signal transducer and activator of transcription-3 (STAT3) pathway [101].…”
Section: Chemoresistance To Cisplatin In Ovarian Cancermentioning
confidence: 99%